Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00492076
Status:
COMPLETED
Last Update Posted:
2008-10-16
First Post:
2007-06-26
Brief Title:
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A Randomised Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract Quantified in Mass Units in Subjects With Perennial Mite Induced Asthma
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma The efficacy is based on reduction in control medication
Detailed Description:
The control of mild-moderate persistent asthma include the need of concomitant medication as inhaled corticosteroids However compliance in perennial asthma is low The aim of this study is to assess the possibility to reduce the need of concomitant medication through a short-course of subcutaneous immunotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None